Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 499-508

  Debing, Yannick ^a   Ramière, Christophe ^b,c,d,e   Dallmeier, Kai ^a   Piorkowski, Géraldine ^f   Trabaud, Mary Anne ^b   Lebossé, Fanny ^b,d,e,g   Scholtès, Caroline ^b,c,d,e   Roche, Magali ^h   Legras Lachuer, Catherine ^h,i   de Lamballerie, Xavier ^f,j   André, Patrice ^b,c,d,e   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CROIX ROUSSE HOSPITAL   (France)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITÉ DE LYON   (France)

^f Aix Marseille University IRD 190 Inserm 1207   (France)

^g CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^h ViroScan3D ^*  (France)

ⁱ University of Lyon   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Chronic hepatitis E; Fidelity; G1634R; Hepatitis E virus; Hypervariable region; Resistance; Ribavirin; RNA dependent RNA polymerase

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; GUANOSINE TRIPHOSPHATE; MYCOPHENOLIC ACID; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; ANTIVIRUS AGENT;

AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DRUG TREATMENT FAILURE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; MALE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPLICON; VIRUS GENOME; VIRUS REPLICATION; TREATMENT FAILURE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS E VIRUS; HUMANS; MUTATION; RIBAVIRIN; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 84977632229     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.002     Document Type: Article

References (35)

1. [1] Behrendt, P., Steinmann, E., Manns, M.P., Wedemeyer, H., The impact of hepatitis E in the liver transplant setting. J Hepatol 61 (2014), 1418–1429.
2. [2] Debing, Y., Neyts, J., Antiviral strategies for hepatitis E virus. Antiviral Res 102 (2014), 106–118.
3. [3] Fujiwara, S., Yokokawa, Y., Morino, K., Hayasaka, K., Kawabata, M., Shimizu, T., Chronic hepatitis E: a review of the literature. J Viral Hepat 21 (2014), 78–89.
4. [4] Sayed, I.M., Vercouter, A.-S., Abdelwahab, S.F., Vercauteren, K., Meuleman, P., Is hepatitis E virus an emerging problem in industrialized countries?. Hepatology, 2015, 10.1002/hep.27990.
5. [5] Kamar, N., Garrouste, C., Haagsma, E.B., Garrigue, V., Pischke, S., Chauvet, C., et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140 (2011), 1481–1489.
6. [6] Alric, L., Bonnet, D., Laurent, G., Kamar, N., Izopet, J., Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. Ann Intern Med 153 (2010), 135–136.
7. [7] Kamar, N., Izopet, J., Tripon, S., Bismuth, M., Hillaire, S., Dumortier, J., et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 370 (2014), 1111–1120.
8. [8] Pischke, S., Hardtke, S., Bode, U., Birkner, S., Chatzikyrkou, C., Kauffmann, W., et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 33 (2013), 722–726.
9. [9] Y. Debing, A. Gisa, Dallmeier, K., Pischke, S., Bremer, B., Manns, M., et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 147 (2014), 1008–1011.
10. [10] P. Shukla, H.T. Nguyen, Faulk, K., Mather, K., Torian, U., Engle, R.E., et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 86 (2012), 5697–5707.
11. [11] Nguyen, H.T., Shukla, P., Torian, U., Faulk, K., Emerson, S.U., Hepatitis E virus genotype 1 infection of swine kidney cells in vitro is inhibited at multiple levels. J Virol 88 (2014), 868–877.
12. [12] Debing, Y., Emerson, S.U., Wang, Y., Pan, Q., Balzarini, J., Dallmeier, K., et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 58 (2014), 267–273.
13. [13] Wang, Y., Zhou, X., Debing, Y., Chen, K., Van Der Laan, L.J.W., Neyts, J., et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 146 (2014), 1775–1783.
14. [14] Koonin, E.V., Gorbalenya, A.E., Purdy, M.A., Rozanov, M.N., Reyes, G.R., Bradley, D.W., Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci U S A 89 (1992), 8259–8263.
15. [15] Bruenn, J.A., A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Res 31 (2003), 1821–1829.
16. [16] Surana, P., Satchidanandam, V., Nair, D.T., RNA-dependent RNA polymerase of Japanese encephalitis virus binds the initiator nucleotide GTP to form a mechanistically important pre-initiation state. Nucleic Acids Res 42 (2014), 2758–2773.
17. [17] Sintchak, M.D., Fleming, M.A., Futer, O., Raybuck, S.A., Chambers, S.P., Caron, P.R., et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85 (1996), 921–930.
18. [18] Steenbergen, R.H.G., Joyce, M.A., Thomas, B.S., Jones, D., Law, J., Russell, R., et al. Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology 58 (2013), 1907–1917.
19. [19] Nguyen, H.T., Torian, U., Faulk, K., Mather, K., Engle, R.E., Thompson, E., et al. A naturally occurring human/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture. J Gen Virol 93 (2012), 526–530.
20. [20] Berto, A., Van der Poel, W.H.M., Hakze-van der Honing, R., Martelli, F., La Ragione, R.M., Inglese, N., et al. Replication of hepatitis E virus in three-dimensional cell culture. J Virol Methods 187 (2013), 327–332.
21. [21] Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6 (2000), 1375–1379.
22. [22] Ortega-Prieto, A.M., Sheldon, J., Grande-Pérez, A., Tejero, H., Gregori, J., Quer, J., et al. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One, 8, 2013, e71039.
23. [23] Hofmann, W.P., Polta, A., Herrmann, E., Mihm, U., Kronenberger, B., Sonntag, T., et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132 (2007), 921–930.
24. [24] Asahina, Y., Izumi, N., Enomoto, N., Uchihara, M., Kurosaki, M., Onuki, Y., et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43 (2005), 623–629.
25. [25] Pfeiffer, J.K., Kirkegaard, K., A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100 (2003), 7289–7294.
26. [26] J. Zeng, H. Wang, Xie, X., Yang, D., Zhou, G., Yu, L., An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Antiviral Res 100 (2013), 1–7.
27. [27] Curti, E., Jaeger, J., Residues Arg283, Arg285, and Ile287 in the nucleotide binding pocket of bovine viral diarrhea virus NS5B RNA polymerase affect catalysis and fidelity. J Virol 87 (2013), 199–207.
28. [28] Baranovich, T., Wong, S.-S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87 (2013), 3741–3751.
29. [29] L. Delang, N. Segura Guerrero, Tas, A., Quérat, G., Pastorino, B., Froeyen, M., et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69 (2014), 2770–2784.
30. [30] Lorenzo, F.R., Tsatsralt-Od, B., Ganbat, S., Takahashi, M., Okamoto, H., Analysis of the full-length genome of hepatitis E virus isolates obtained from farm pigs in Mongolia. J Med Virol 79 (2007), 1128–1137.
31. [31] Lu, Y.-H., Qian, H.-Z., Hu, A.-Q., Ren, H., Qin, X., Jiang, Q.-W., et al. Duration of viraemia in Chinese acute sporadic hepatitis E. Eur J Clin Microbiol Infect Dis 33 (2014), 755–759.
32. [32] P. Shukla, H.T. Nguyen, Torian, U., Engle, R.E., Faulk, K., Dalton, H.R., et al. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A 108 (2011), 2438–2443.
33. [33] Lhomme, S., Abravanel, F., Dubois, M., Sandres-Saune, K., Mansuy, J.-M., Rostaing, L., et al. Characterization of the polyproline region of the hepatitis E virus in immunocompromised patients. J Virol 88 (2014), 12017–12025.
34. [34] Johne, R., Reetz, J., Ulrich, R.G., Machnowska, P., Sachsenröder, J., Nickel, P., et al. An ORF1-rearranged hepatitis E virus derived from a chronically infected patient efficiently replicates in cell culture. J Viral Hepat 21 (2014), 447–456.
35. [35] Dao Thi, V.L., Debing, Y., Wu, X., Rice, C.M., Neyts, J., Moradpour, D., et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology, 2015, 10.1053/j.gastro.2015.09.011.